Ocular Therapeutix Reports Third Quarter 2026 Financial Results, Provides Business Update
BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), an integrated biopharmaceutical company in the retina space, reported financial results on Monday for the third quarter ended September 30, 2026, and provided recent business highlights including upcoming New Drug Application (NDA) submission plans to the U.S. Food and Drug Administration (FDA) for Axpaxli (also known as OTX-TKI), its investigational product candidate for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinal diseases. Total net revenue was $12.9 million for the third quarter of 2026, compared with $14.5 million for the prior-year quarter.
BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), an integrated biopharmaceutical company in the retina space, reported financial results on Monday for the third quarter ended September 30, 2026, and provided recent business highlights including upcoming New Drug Application (NDA) submission plans to the U.S. Food and Drug Administration (FDA) for Axpaxli (also known as OTX-TKI), its investigational product candidate for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinal diseases. Total net revenue was $12.9 million for the third quarter of 2026, compared with $14.5 million for the prior-year quarter.
What's Your Reaction?
